Revvity, Inc. (RVTY) Debt to Assets Ratio: 0.29%
The debt to assets ratio for Revvity, Inc. (RVTY) is 0.29% as of Wednesday, June 17, 2026.
RVTY Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.29%
RVTY Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Revvity, Inc. (RVTY) | $10.91B | 0.29% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.42% |
| Baxter International Inc. (BAX)vs › | $10.19B | 0.50% |
| Align Technology, Inc. (ALGN)vs › | $12.43B | 0.02% |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 0.22% |
| Solventum Corporation (SOLV)vs › | $12.91B | 0.35% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.78B | 0.43% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.05B | 0.13% |
| Tempus AI, Inc. (TEM)vs › | $8.51B | 0.58% |
| DaVita Inc. (DVA)vs › | $13.52B | 0.86% |
Leverage Ratios Comparison
Debt/Assets
0.3%
Debt/Equity
0.48
Current Ratio
1.68
Interest Coverage
3.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Revvity, Inc. Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. Debt to Assets Ratio FAQ
- What is the debt to assets ratio for Revvity, Inc. (RVTY)?
- The debt to assets ratio for RVTY stock is 0.29%.
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh